InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,909.46
(
0.19%
)
Post# of 251796
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119614
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 110117

Monday, 11/30/2015 11:03:31 AM

Monday, November 30, 2015 11:03:31 AM

Post# of 251796
BMY/ABBV—FDA approves Empliciti (elotuzumab) for second-third-fourth-line MM in combination with Revlimid and dexamethasone:

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474684.htm

ABBV (then ABT) acquired Empliciti in its 2010 buyout of Facet Biotech (the successor company to PDLI) (#msg-47606240); BMY partnered with PDLI in 2008.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up